ALSO NOTED: Ranbaxy recalls tainted Gebapentin;BMS gets Abilify on fast track for bipolar kids;

> After discovering impurities in the pills, Ranbaxy Laboratories is recalling 73 million tablets of its epilepsy remedy Gebapentin from the U.S. market. Report

> Bristol-Myers Squibb and partner Otsuka Pharmaceutical said the FDA will fast-track their application to market the antipsychotic Abilify for use in children with bipolar disorder. Report

> India's Orchid Chemicals & Pharmaceuticals got the FDA's nod for its version of the antibiotic Cefpodoxime Proxetil, marketed by Pfizer under the brand name Vantin. Report

> Surgical instruments maker Gyrus was hit with a patent infringement suit by rival ArthroCare. Report

And Finally... Governments meet next week to hammer out a flu-virus sharing agreement so scientists can better track the evolution of H5N1. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.